Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other regimens. The aim of this study was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourrier, Nicole, Landego, Ivan, Bucher, Oliver, Squires, Mandy, Streu, Erin, Hibbert, Irena, Whiteside, Theresa, Gibson, Spencer B., Geirnaert, Marc, Johnston, James B., Dawe, David E., Banerji, Versha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818183/
https://www.ncbi.nlm.nih.gov/pubmed/35123433
http://dx.doi.org/10.1186/s12885-022-09256-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818183/
https://www.ncbi.nlm.nih.gov/pubmed/35123433
http://dx.doi.org/10.1186/s12885-022-09256-2

Ejemplares similares